Literature DB >> 11814445

Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC.

Vito Ferro1, Caiping Li, Kym Fewings, Maria C Palermo, Robert J Linhardt, Toshihiko Toida.   

Abstract

The promising new anticancer agent, PI-88, is prepared by the sulfonation of the oligosaccharide phosphate fraction of the extracellular phosphomannan produced by the yeast Pichia (Hansenula) holstii NRRL Y-2448. The composition of the oligosaccharide phosphate fraction was determined by capillary electrophoresis (CE) with indirect UV detection using 6 mM potassium sorbate at pH 10.3 as the background electrolyte. Further confirmation of the composition was obtained by HPLC analysis of a sample dephosphorylated by treatment with alkaline phosphatase. The structure of the hexasaccharide component has been determined by isolation and NMR spectroscopic analysis of its dephosphorylated derivative. Additionally, the structure of a second, previously undetected tetrasaccharide component (a hexosamine) has been determined by isolation and NMR spectroscopic analysis of the acetate of its dephosphorylated derivative. It is demonstrated that CE is an ideal method for the quality control of the oligosaccharide phosphate fraction for use in the production of PI-88.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814445     DOI: 10.1016/s0008-6215(01)00300-7

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  8 in total

1.  A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

Authors:  Karl D Lewis; William A Robinson; Michael J Millward; Alex Powell; Timothy J Price; Damien B Thomson; Euan T Walpole; Andrew M Haydon; Brian R Creese; Kaye L Roberts; John R Zalcberg; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2007-09-20       Impact factor: 3.850

2.  Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific manner†.

Authors:  Ryan J Blackler; Dylan W Evans; David F Smith; Richard D Cummings; Cory L Brooks; Thomas Braulke; Xinyu Liu; Stephen V Evans; Sven Müller-Loennies
Journal:  Glycobiology       Date:  2015-10-26       Impact factor: 4.313

3.  Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.

Authors:  Xian-Jun Liang; Ling Yuan; Jie Hu; Hong-Hua Yu; Tao Li; Shao-Fen Lin; Shi-Bo Tang
Journal:  Mol Vis       Date:  2012-06-20       Impact factor: 2.367

Review 4.  Carbohydrate-related inhibitors of dengue virus entry.

Authors:  Kazuya I P J Hidari; Tomoko Abe; Takashi Suzuki
Journal:  Viruses       Date:  2013-02-06       Impact factor: 5.048

Review 5.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

Review 6.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02

Review 7.  Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Authors:  Aikaterini Berdiaki; Monica Neagu; Eirini-Maria Giatagana; Andrey Kuskov; Aristidis M Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Biomolecules       Date:  2021-03-08

Review 8.  From Cancer to COVID-19: A Perspective on Targeting Heparan Sulfate-Protein Interactions.

Authors:  Mohit Chhabra; Gareth G Doherty; Nicholas W See; Neha S Gandhi; Vito Ferro
Journal:  Chem Rec       Date:  2021-06-19       Impact factor: 6.935

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.